Biotechnology company
Appears in 5 stories · Last updated Nov 2, 2026
Sponsor of Krascendo 1; developer of divarasib
Five years after the first KRAS inhibitor reached the market, a next-generation drug beat the existing ones head-to-head. In the Phase III Krascendo 1 trial, divarasib cut the risk of death by 44% and nearly doubled response rates in patients with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC).
Updated Nov 2
Maker of Lucentis, the reference product Lucamzi copies
After four years and two FDA rejections, Xbrane Biopharma has US approval for its copy of Lucentis, one of the world's best-selling eye drugs. Xbrane announced the approval on October 27, two days before the FDA's October 29 review deadline.
Updated Oct 31
Roche's US commercialization arm for Enspryng
The FDA approved Roche's Enspryng for thyroid eye disease on October 15, the first and only at-home subcutaneous treatment for the condition. Patients or caregivers inject the drug with a prefilled syringe or pen after a healthcare provider's training, with no infusion clinic visits.
Updated Oct 17
As of October 2026: Lead sponsor of evERA trial; submitted giredestrant NDAs to FDA
Patients with estrogen receptor (ER)-positive advanced breast cancer who progress on a CDK4/6 inhibitor have few options left. The Phase III evERA trial found that giredestrant, a pill that degrades the estrogen receptor, plus everolimus cut the risk of progression or death by 44% overall and 62% in ESR1-mutated tumors.
Updated Oct 2
As of September 2026: Expanding its Hillsboro manufacturing campus
Genentech broke ground Sept. 28 on a $750 million expansion of its manufacturing campus in Hillsboro, Oregon. The project adds 211,000 square feet and nearly doubles the size of the site.
Updated Sep 30
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
